Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition.
Alterations to the mucosal environment of the female genital tract, such as genital inflammation, have been associated with increased HIV acquisition in women. As the microbiome and hormonal contraceptives can affect vaginal mucosal immunity, we hypothesized these components may interact in the cont...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-12-01
|
| Series: | PLoS Pathogens |
| Online Access: | https://doi.org/10.1371/journal.ppat.1009097 |
| _version_ | 1819029587864059904 |
|---|---|
| author | Laura Noël-Romas Michelle Perner Refilwe Molatlhegi Christina Farr Zuend Amanda Mabhula Sarah Hoger Alana Lamont Kenzie Birse Alicia Berard Stuart McCorrister Garett Westmacott Al Leslie Vanessa Poliquin Renee Heffron Lyle R McKinnon Adam D Burgener |
| author_facet | Laura Noël-Romas Michelle Perner Refilwe Molatlhegi Christina Farr Zuend Amanda Mabhula Sarah Hoger Alana Lamont Kenzie Birse Alicia Berard Stuart McCorrister Garett Westmacott Al Leslie Vanessa Poliquin Renee Heffron Lyle R McKinnon Adam D Burgener |
| author_sort | Laura Noël-Romas |
| collection | DOAJ |
| description | Alterations to the mucosal environment of the female genital tract, such as genital inflammation, have been associated with increased HIV acquisition in women. As the microbiome and hormonal contraceptives can affect vaginal mucosal immunity, we hypothesized these components may interact in the context of HIV susceptibility. Using previously published microbiome data from 685 women in the CAPRISA-004 trial, we compared relative risk of HIV acquisition in this cohort who were using injectable depot medroxyprogesterone acetate (DMPA), norethisterone enanthate (NET-EN), and combined oral contraceptives (COC). In women who were Lactobacillus-dominant, HIV acquisition was 3-fold higher in women using DMPA relative to women using NET-EN or COC (OR: 3.27; 95% CI: 1.24-11.24, P = 0.0305). This was not observed in non-Lactobacillus-dominant women (OR: 0.95, 95% CI: 0.44-2.15, P = 0.895) (interaction P = 0.0686). Higher serum MPA levels associated with increased molecular pathways of inflammation in the vaginal mucosal fluid of Lactobacillus-dominant women, but no differences were seen in non-Lactobacillus dominant women. This study provides data suggesting an interaction between the microbiome, hormonal contraceptives, and HIV susceptibility. |
| first_indexed | 2024-12-21T06:16:38Z |
| format | Article |
| id | doaj.art-4aa8c2a61e09450bbe96238e45e65caa |
| institution | Directory Open Access Journal |
| issn | 1553-7366 1553-7374 |
| language | English |
| last_indexed | 2024-12-21T06:16:38Z |
| publishDate | 2020-12-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Pathogens |
| spelling | doaj.art-4aa8c2a61e09450bbe96238e45e65caa2022-12-21T19:13:23ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742020-12-011612e100909710.1371/journal.ppat.1009097Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition.Laura Noël-RomasMichelle PernerRefilwe MolatlhegiChristina Farr ZuendAmanda MabhulaSarah HogerAlana LamontKenzie BirseAlicia BerardStuart McCorristerGarett WestmacottAl LeslieVanessa PoliquinRenee HeffronLyle R McKinnonAdam D BurgenerAlterations to the mucosal environment of the female genital tract, such as genital inflammation, have been associated with increased HIV acquisition in women. As the microbiome and hormonal contraceptives can affect vaginal mucosal immunity, we hypothesized these components may interact in the context of HIV susceptibility. Using previously published microbiome data from 685 women in the CAPRISA-004 trial, we compared relative risk of HIV acquisition in this cohort who were using injectable depot medroxyprogesterone acetate (DMPA), norethisterone enanthate (NET-EN), and combined oral contraceptives (COC). In women who were Lactobacillus-dominant, HIV acquisition was 3-fold higher in women using DMPA relative to women using NET-EN or COC (OR: 3.27; 95% CI: 1.24-11.24, P = 0.0305). This was not observed in non-Lactobacillus-dominant women (OR: 0.95, 95% CI: 0.44-2.15, P = 0.895) (interaction P = 0.0686). Higher serum MPA levels associated with increased molecular pathways of inflammation in the vaginal mucosal fluid of Lactobacillus-dominant women, but no differences were seen in non-Lactobacillus dominant women. This study provides data suggesting an interaction between the microbiome, hormonal contraceptives, and HIV susceptibility.https://doi.org/10.1371/journal.ppat.1009097 |
| spellingShingle | Laura Noël-Romas Michelle Perner Refilwe Molatlhegi Christina Farr Zuend Amanda Mabhula Sarah Hoger Alana Lamont Kenzie Birse Alicia Berard Stuart McCorrister Garett Westmacott Al Leslie Vanessa Poliquin Renee Heffron Lyle R McKinnon Adam D Burgener Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition. PLoS Pathogens |
| title | Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition. |
| title_full | Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition. |
| title_fullStr | Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition. |
| title_full_unstemmed | Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition. |
| title_short | Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition. |
| title_sort | vaginal microbiome hormonal contraceptive interactions associate with the mucosal proteome and hiv acquisition |
| url | https://doi.org/10.1371/journal.ppat.1009097 |
| work_keys_str_mv | AT lauranoelromas vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT michelleperner vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT refilwemolatlhegi vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT christinafarrzuend vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT amandamabhula vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT sarahhoger vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT alanalamont vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT kenziebirse vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT aliciaberard vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT stuartmccorrister vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT garettwestmacott vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT alleslie vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT vanessapoliquin vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT reneeheffron vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT lylermckinnon vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition AT adamdburgener vaginalmicrobiomehormonalcontraceptiveinteractionsassociatewiththemucosalproteomeandhivacquisition |